Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

In Patients We Trust: Reliability of Self-Reported Weight and Height in Nuclear Medicine Patients.

Blum KS, Büsch N, Beyer T, Rausch I, Freudenberg LS.

J Nucl Med Technol. 2019 Jun;47(2):133-136. doi: 10.2967/jnmt.118.216317. Epub 2018 Nov 9.

PMID:
30413597
2.

An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement.

Freudenberg LS, Hicks RJ, Beyer T.

J Nucl Med. 2019 Apr;60(4):480-485. doi: 10.2967/jnumed.118.218073. Epub 2018 Nov 2.

PMID:
30389815
3.

[Development of a national competency-based learning objective catalogue for undergraduate medical education in Germany].

Marienhagen J, Brenner W, Buck A, Franzius C, Freudenberg LS, Gotthardt M, Lindner O, Mottaghy FM, Hellwig D.

Nuklearmedizin. 2018 Aug;57(4):137-145. doi: 10.3413/Nukmed-0969-18-03. Epub 2018 Aug 20. German.

PMID:
30125926
4.

An international survey on hybrid imaging: do technology advances preempt our training and education efforts?

Beyer T, Hicks R, Brun C, Antoch G, Freudenberg LS.

Cancer Imaging. 2018 Apr 26;18(1):15. doi: 10.1186/s40644-018-0148-6.

5.

[Nuclear medicine in Europe: education].

Hellwig D, Freudenberg LS, Mottaghy FM, Franzius C, Krause T, Garai I, Biermann M, Grüning T, Leitha T, Gotthardt M.

Nuklearmedizin. 2012;51(2):35-46. doi: 10.3413/Nukmed-0475-12-02. Epub 2012 Mar 6. German.

PMID:
22395746
6.

The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond.

Beyer T, Freudenberg LS, Czernin J, Townsend DW.

Insights Imaging. 2011 Jun;2(3):235-246. Epub 2011 Mar 25.

7.

Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.

Rosenbaum-Krumme SJ, Freudenberg LS, Jentzen W, Bockisch A, Nagarajah J.

Clin Nucl Med. 2012 Mar;37(3):e47-52. doi: 10.1097/RLU.0b013e3182443ca6.

PMID:
22310270
8.

The future of hybrid imaging-part 2: PET/CT.

Beyer T, Townsend DW, Czernin J, Freudenberg LS.

Insights Imaging. 2011 Jun;2(3):225-34. doi: 10.1007/s13244-011-0069-4. Epub 2011 Feb 20.

9.

Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ.

Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S48-56. doi: 10.1007/s00259-011-1773-5. Epub 2011 Apr 12. Review.

PMID:
21484380
10.

Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections.

Jentzen W, Freudenberg L, Bockisch A.

Q J Nucl Med Mol Imaging. 2011 Feb;55(1):21-43. Review.

PMID:
21386783
11.

Variations in clinical PET/CT operations: results of an international survey of active PET/CT users.

Beyer T, Czernin J, Freudenberg LS.

J Nucl Med. 2011 Feb;52(2):303-10. doi: 10.2967/jnumed.110.079624. Epub 2011 Jan 13.

12.

Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.

Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A.

Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2267-76. doi: 10.1007/s00259-010-1565-3. Epub 2010 Jul 27.

PMID:
20661558
13.

The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A.

Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2298-306. doi: 10.1007/s00259-010-1532-z. Epub 2010 Jul 13.

PMID:
20625723
14.

PET versus PET/CT dual-modality imaging in evaluation of lung cancer.

Freudenberg LS, Rosenbaum SJ, Beyer T, Bockisch A, Antoch G.

Thorac Surg Clin. 2010 Feb;20(1):25-30. doi: 10.1016/j.thorsurg.2009.12.003.

PMID:
20378058
15.

Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.

Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, Eising EG, Knust EJ, Bockisch A, Jentzen W.

Exp Clin Endocrinol Diabetes. 2010 Jul;118(7):393-9. doi: 10.1055/s-0029-1225350. Epub 2009 Oct 23.

PMID:
19856257
16.

Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging.

Bockisch A, Freudenberg LS, Schmidt D, Kuwert T.

Semin Nucl Med. 2009 Jul;39(4):276-89. doi: 10.1053/j.semnuclmed.2009.03.003. Review.

PMID:
19497404
17.

[Impact of nuclear medicine imaging techniques for lymph node surgery].

Freudenberg LS, Holl G, Müller SP, Rosenbaum-Krumme SJ, Sciuk J, Bockisch A.

Urologe A. 2009 Jan;48(1):19-25. doi: 10.1007/s00120-008-1754-x. Review. German.

PMID:
19037623
18.

Breast cancer staging in a single session: whole-body PET/CT mammography.

Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, Kimmig KR, Forsting M, Bockisch A, Antoch G.

J Nucl Med. 2008 Aug;49(8):1215-22. doi: 10.2967/jnumed.108.052050. Epub 2008 Jul 16.

19.

Whole-body PET/CT-mammography for staging breast cancer: initial results.

Heusner TA, Freudenberg LS, Kuehl H, Hauth EA, Veit-Haibach P, Forsting M, Bockisch A, Antoch G.

Br J Radiol. 2008 Sep;81(969):743-8. doi: 10.1259/bjr/69647413. Epub 2008 May 28.

PMID:
18508873
20.

Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A.

J Nucl Med. 2008 Jun;49(6):1017-23. doi: 10.2967/jnumed.107.047159. Epub 2008 May 15.

Supplemental Content

Loading ...
Support Center